What caused the intraday rise in 2181.HK stock today?

The intraday rise to HK$0.51 was driven by a volume spike of 94,000 shares. Short-term buying and momentum indicators triggered the move; no single public catalyst was confirmed. Watch for clinical or licensing updates that could have supported the buying.

How does Meyka AI assess 2181.HK stock valuation?

Meyka AI flags mixed signals: EPS is -0.01 and PE is -51.00, while price-to-book is high at 18.67. The grade is B (68.43). Valuation suggests premium pricing tied to pipeline prospects rather than current earnings.

What price targets and upside does the model show for 2181.HK stock?

Meyka AI's forecast model projects monthly HK$0.75, quarterly HK$0.63, and yearly HK$0.70. From HK$0.51 today, that implies upside of 47.06% (monthly), 23.53% (quarter), and 37.78% (year). Forecasts are projections, not guarantees.

What is a practical trading plan after the volume spike in 2181.HK stock?

Require a confirmed close above HK$0.51 on rising volume, use a stop below HK$0.49 or HK$0.43, and scale out near HK$0.63–HK$0.75. Size positions small given leverage and inventory risks.

HK Stocks

2181.HK Mabpharm (HKSE) jumps 18.60% intraday on volume spike: watch for follow-through

ByDanny Kontos March 12, 2026March 12, 2026

A sharp intraday volume spike lifted 2181.HK stock to HK$0.51 on 12 Mar 2026, up 18.60% from yesterday. The move came on 94,000 shares traded, above the 50-day average of 79,614. Intraday buyers pushed the price well above the 50-day average of HK$0.49, creating a short-term momentum opportunity for traders watching follow-through in Hong Kong (HKSE). We examine price action, technical signals, fundamentals, Meyka AI’s grade and model forecasts to frame a volume-spike trading approach.